Uptake of health economic evaluations alongside clinical trials in Australia: an observational study
Current uptake of health economic evaluations alongside Australian-led clinical trials is low, with uptake higher among the subset of ACTA network trials. This is despite economic evidence playing an increasingly prominent role in health system management, as well as rising health expenditure, limited budgets, and competing demands. There is significant opportunity to embed health economic evaluations alongside clinical trials, particularly phase 3 trials, to increase research outputs and optimize research translation. Investing in clinical trial networks that support funding for a health economist or a health economic evaluation may be an effective strategy to increase the uptake of health economic evaluations alongside trials.
Authors
- Amy Grove (ORCID: https://orcid.org/0000-0002-8027-7274)
- Rachael L. Morton (ORCID: https://orcid.org/0000-0001-7834-0572)
- Alayna Carrandi (ORCID: https://orcid.org/0000-0002-5711-0417)
- Alisa M. Higgins (ORCID: https://orcid.org/0000-0001-8295-7559)
- Helen Skouteris (ORCID: https://orcid.org/0000-0001-9959-5750)
- Conni Wells
- Richard Norman (ORCID: https://orcid.org/0000-0002-3112-3893)
Institutions
- The University of Sydney (AU)
- Curtin University (AU)
- University of Warwick (GB)
- Australian and New Zealand Intensive Care Society (AU)
- National Health and Medical Research Council (AU)
- Monash University (AU)
Publication Details
- Journal
- Trials
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1186/s13063-024-08562-3
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- National Institute for Health and Care Research
- National Health and Medical Research Council
- Faculty of Medicine and Health, University of Sydney
- National Institute for Health Research Applied Research Collaboration West